Arbutus Biopharma Corporation
ABUS
$3.14
$0.020.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -26.62% | -71.25% | -62.89% | -77.09% | -65.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.62% | -71.25% | -62.89% | -77.09% | -65.65% |
| Cost of Revenue | -49.84% | -29.23% | -12.10% | -15.72% | -23.47% |
| Gross Profit | 53.07% | 16.61% | -6.01% | -19.70% | 7.69% |
| SG&A Expenses | 65.30% | -22.34% | 26.20% | -4.32% | 20.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.93% | -27.68% | -2.42% | -13.06% | -16.67% |
| Operating Income | 23.65% | 18.18% | -12.36% | -11.92% | 2.07% |
| Income Before Tax | 35.11% | 1.92% | -15.81% | -9.40% | 11.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.11% | 1.92% | -15.81% | -9.40% | 11.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.11% | 1.92% | -15.81% | -9.40% | 11.95% |
| EBIT | 23.65% | 18.18% | -12.36% | -11.92% | 2.07% |
| EBITDA | 23.94% | 18.34% | -12.51% | -12.03% | 2.35% |
| EPS Basic | 42.32% | 13.08% | -2.33% | -0.69% | 18.72% |
| Normalized Basic EPS | 33.62% | 29.78% | 2.40% | -1.45% | 13.24% |
| EPS Diluted | 40.05% | 13.08% | -2.33% | -0.69% | 18.01% |
| Normalized Diluted EPS | 33.62% | 29.78% | 2.40% | -1.45% | 13.24% |
| Average Basic Shares Outstanding | 12.52% | 12.83% | 13.23% | 8.65% | 8.35% |
| Average Diluted Shares Outstanding | 12.52% | 12.83% | 13.23% | 8.65% | 8.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
